Clear Search

Showing 4 results for “Walsh J”.

May 2023

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Axial Involvement: Results From Two Phase 3 Studies

Arthritis Res Ther. 2023;25(1):56 doi 10.1186/s13075-023-03027-5

Evidence from two phase 3 RCTs showed that patients with PsA and axial involvement had greater responses when treated with a once-daily oral dose of 15 mg upadacitinib versus placebo, and a similar or greater response versus adalimumab. Safety results were comparable between patients with or without axial involvement.

more…

December 2022

Real-world Treatment Patterns and Use of Adjunctive Pain and Anti-inflammatory Medications Among Patients with Psoriatic Arthritis Treated With IL-17A Inhibitors In The United States

J Manag Care Spec Pharm. 2022 doi: 10.18553/jmcp.2022.22144

In this study ixekizumab and secukinumab patients had similar treatment patterns. It was also surmised that the use of adjunctive pain and anti-inflammatory medications were similar between therapies. In coming to this conclusion investigators aimed to compare treatment patterns and use of pain and anti-inflammatory medications between patients with PsA initiating ixekizumab and secukinumab in two cohorts of patients from…(add here where is the population coming from).

more…

Keywords:

September 2022

Efficacy and Safety of Ixekizumab Treatment in Patients with Axial Spondyloarthritis: 2-year Results from COAST

RMD Open. 2022 doi: 10.1136/rmdopen-2021-002165

This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.

more…

June 2022

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials

Advance Therapy,2022 Jun;39(6):2806-2819. doi.org/10.1007/s12325−022−02132−2

van der Horst-Bruinsma et al., carried out a post-hoc analysis to confirm that the clinical presentations and responses to ixekizumab therapy may differ in male and female patients.

more…